Plasma biomarkers for lung cancer diagnosis

项目摘要-摘要 由于低剂量CT（LDCT）早期发现肺癌可以降低死亡率， 每年的LDCT筛查现在由医疗保险和医疗补助服务中心报销 (CMS)吸烟者通过医疗保险。超过四分之一的屏幕 发现不确定的肺结节（PN）。4%的PN是早期肺癌，而 其余96%为良性。因此，LDCT存在过度诊断。的需求尚未得到满足 LDCT随访的反射测试，将重点放在4%的吸烟者需要的护理上。 该项目是开发和验证血浆测试，用于区分恶性和良性PN， 基线LDCT。将来使用该试验来区分恶性和良性PN， 通过减少过度诊断来补充LDCT用于肺癌检测， 减少死亡和成本。

Project Summary-Abstract Because the early detection of lung cancer by low-dose CT (LDCT) can reduce the mortality, annual LDCT screening is now being reimbursed by Centers for Medicare & Medicaid Services (CMS) for smokers insured through Medicare. However, more than one-quarter of screens discover indeterminate pulmonary nodules (PNs). 4% of PNs are early-stage lung cancers, while the remaining 96% are benign. Therefore, LDCT has over-diagnosis. There is an unmet need for a reflex test for LDCT follow-up to focus care on the 4% smokers need it. The objective of this project is to develop and validate a plasma test for differentiating malignant from benign PNs at baseline LDCT. Future use of this test for discriminating between malignant and benign PNs will complement LDCT for lung cancer detection by reducing the over-diagnosis, and eventually decrease the deaths and cost.